Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
privosegtor (OCS-05) / Oculis
ACUITY, NCT04762017: OCS-05 in Patients with Acute Optic Neuritis	Completed	2	36	Europe	OCS-05 +SoC (corticosteroid) IV administration, Placebo + SoC (corticosteroid) IV administration	Oculis, Neurotrials	Optic Neuritis, Optic; Neuritis, with Demyelination	09/24	09/24
ACT-02 / Accure Therap
NCT06268847: Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms	Completed	N/A	92	Europe	Placebo, ACT01, ACT02	Abyss Ingredients, Eurofins	Atopic Dermatitis, Eczema	04/24	07/24
ACT-03 / Accure Therap
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
privosegtor (OCS-05) / Oculis
ACUITY, NCT04762017: OCS-05 in Patients with Acute Optic Neuritis	Completed	2	36	Europe	OCS-05 +SoC (corticosteroid) IV administration, Placebo + SoC (corticosteroid) IV administration	Oculis, Neurotrials	Optic Neuritis, Optic; Neuritis, with Demyelination	09/24	09/24
ACT-02 / Accure Therap
NCT06268847: Efficacy of Marine By-product Hydrolysate on the Reduction of Atopic Dermatitis Symptoms	Completed	N/A	92	Europe	Placebo, ACT01, ACT02	Abyss Ingredients, Eurofins	Atopic Dermatitis, Eczema	04/24	07/24
ACT-03 / Accure Therap
No trials found